Loading clinical trials...
Loading clinical trials...
An Open-label, Multicentre, Randomised Phase II Study of Pazopanib in Combination With Pemetrexed in First-line Treatment of Subjects With Predominantly Non-squamous Cell Stage IIIBwet/IV Non-small Cell Lung Cancer
Conditions
Interventions
pazopanib and pemetrexed
pemetrexed and cisplatin
Locations
2
Denmark
GSK Investigational Site
Herlev, Denmark
GSK Investigational Site
Sutton, Surrey, United Kingdom
Start Date
July 1, 2009
Primary Completion Date
March 1, 2011
Completion Date
March 1, 2011
Last Updated
June 20, 2013
NCT07219251
NCT06405230
NCT04940936
NCT06659042
NCT06769295
NCT06648317
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions